PRAXIS: Quality Management in Research Virtual Workshop
Posted: 15 March 2022 Learn how to improve your unit processes, minimise delays, and increase the quality of your research by enrolling into PRAXIS Australia’s Quality by Design virtual workshop. On completion, you will be able to: Explain…
Stable Cell Line for Production of PAT-DX3 Established
Posted: 2 March 2022 BioMelbourne Network Member Patrys Limited, a therapeutic antibody development company, is pleased to announce it has identified and selected an optimised stable cell line for production of its full-sized IgG deoxymab, PAT-DX3. This allows…
ENA Respiratory and COPD Foundation to Develop Pan-Antiviral Nasal Spray
Posted: 24 February 2022 ENA Respiratory, a clinical-stage pharmaceutical company developing INNA-051, a first-in-class broad-spectrum antiviral innate immunomodulator for pre- and post-exposure prophylaxis of respiratory viral infections, including COVID-19 in populations at-risk of complications, and the COPD Foundation, a…
St Vincent’s Hospital Melbourne delivers half a million COVID-19 vaccinations
Posted: 10 February 2022 St Vincent’s Hospital Melbourne has now administered more than half a million COVID-19 vaccination doses across its vaccination programs with support from its newly-skilled workforce who have responded to the call to vaccinate and…
Tessara Therapeutics positions for growth with major appointments to management team
Posted: 10 February 2022 Tessara Therapeutics, an Australian biotechnology company developing synthetic human brain micro-tissues as drug screening and neuro-regenerative medicine platforms, has accelerated its growth and cemented its future with a series of significant senior appointments as…
Planet Innovation and Lumos Diagnostics collaborate to establish local RAT manufacturing facility
Posted: 7 February 2022 Planet Innovation (PI), Australia’s leading healthtech innovation and commercialisation company, and Lumos Diagnostics (Lumos), a rapid point-of-care diagnostics company, with support from the Victorian State Government, will establish a $17.2 million Rapid Diagnostics Manufacturing…
Cytiva fuels biotech development in Australia and New Zealand
Posted: 2 February 2022 VivaZome Therapeutics wins top prize with its potential to provide off-the-shelf regenerative medicines. Part of Cytiva’s BioChallenge global series, the inaugural challenge for the Australia and New Zealand region received 32 applications from various…
COVALIA study update: Safety Results from needle-free SARS-CoV2 DNA vaccine phase 1 trial
Posted: 21 January 2022 First needle-free SARS-CoV2 DNA vaccine tested in Australia is well tolerated No safety concerns were observed Ongoing study enrolment for booster dose Technovalia, an Australian biotech vaccine developer has announced the interim safety results…
Sophie Stocker receives grant to lead charge for precision medicine research
Posted: 20 December 2021 Dr. Sophie Stocker, a senior lecturer at the University of Sydney, has been awarded a Ramaciotti Health Investment Grant of close to $100,000 by the Clive and Vera Ramaciotti Foundations to undertake medical research for precision medicine using a…
MedTech Innovator Asia Pacific 2022 Accelerator Program – Applications now open
Posted: 13 December 2021 About MedTech Innovator Asia Pacific MedTech Innovator is the medical technology industry’s global showcase and accelerator for innovative medical device, digital health and diagnostic companies. The mission is to improve the lives of patients…
2022 ANDHealth+ cohort announced
Posted: 13 December 2021 BioMelbourne Network Member, ANDHealth, have welcomed the five companies selected for the 2022 ANDHealth+ program, Australia’s leading commercialisation program for digital health. The successful companies were announced by Dr Katie Allen, MP, Member for…
Inhaled AD-214 passes first development milestone
Posted: 13 December 2021 BioMelbourne Network Member, AdAlta Limited, the clinical stage drug discovery company developing novel therapeutic products from its i-body platform, is pleased to announce that initial testing of AD-214 in nebulisation devices has exceeded expectations.…
